Das Glori, Wong Stephen T C, Zhao Hong
Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX 77030, USA.
Department of Biomedical Engineering, Texas A&M University School of Medicine, College Station, TX 77843, USA.
Cancers (Basel). 2024 Oct 18;16(20):3525. doi: 10.3390/cancers16203525.
This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.
本评论聚焦于2024年9月13日发表在《自然·医学》上的DESTINY-Breast12研究，该研究评估了曲妥珠单抗德鲁昔单抗（T-DXd）治疗HER2阳性晚期乳腺癌（包括伴有脑转移的患者）的疗效。我们强调T-DXd在治疗原本分类为HER2阴性或HER2低表达肿瘤的脑转移方面具有更广泛的临床潜力，这超出了其目前在乳腺癌治疗中的应用范围。T-DXd的这种扩展应用可为应对具有挑战性脑转移的患者带来新希望，满足对有效治疗方案的迫切需求。
